| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4216101 | Revue des Maladies Respiratoires Actualités | 2011 | 4 Pages |
Abstract
Positron emission tomography (PET) using [18F]-fluoro-2-desoxy-D-glucose, complements conventional imaging evaluation of patients with lung cancer. The strength of PET scanning lies in the detection of nodal and extrathoracic metastases. PET scanning is also currently being studied in the assessment of prognosis and metabolic response to systemic therapies. Areas requiring further development include using respiratory gating technology, increasing availability of PET hypoxia tracers for radiotherapy planning and optimizing cost effectiveness of molecular imaging.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
D. Taïeb, L. Tessonnier, S. Cammilleri, O. Mundler,